I was heartened to read recently that Kentucky has surpassed the $1 billion mark in total opioid settlement funds secured to ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine ...

South Carolina recently announced the promotions of Chandler Messer and Wilson Springs to Assistant Property Managers.

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA ...

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.